Horizon Pharma price target raised to $25 from $18 at Stifel Stifel increased its price target on Horizon as the firm thinks that the company's acquisition of Vidara has left it in "ideal position" to become profitable and meet its revenue and EBITDA guidance. The firm thinks the company's drug portfolio is poised to perform well, and keeps a Buy rating on the shares.
Horizon Pharma files to sell 11.66M shares for existing holders Horizon Pharma announced a proposed underwritten secondary offering of 11.66M of its ordinary shares held by certain of its existing shareholders. Morgan Stanley, Citigroup, Cowen and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.